Dr Luis Angel Diaz Cruz, M D | |
A La Orden Shopping Center 2nd Fl 600, 2821 Pr-167, Toa Baja, PR 00950-1502 | |
(787) 710-2532 | |
Not Available |
Full Name | Dr Luis Angel Diaz Cruz |
---|---|
Gender | Male |
Speciality | Nephrology |
Experience | 14 Years |
Location | A La Orden Shopping Center 2nd Fl 600, Toa Baja, Puerto Rico |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790133718 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RN0300X | Internal Medicine - Nephrology | 022351 (Puerto Rico) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Auxilio Mutuo Hospital | Hato rey, PR | Hospital |
Entity Name | Pr Renal Health And Research Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1083923114 PECOS PAC ID: 9739377862 Enrollment ID: O20101216000155 |
News Archive
Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS® CRT-D. The exclusive expanded indication is effective immediately and makes Boston Scientific CRT-Ds the only devices approved by the FDA for patients in all New York Heart Association (NYHA) classes of heart failure.
Spanish researchers have analysed the effect of endurance running training on the stiffness index, a variable that is directly related to bone quality. The results confirm that the greater the race distance that is trained, the better; this can be used, therefore, to prevent the progressive decline in bone mineral density that occurs with age.
Researchers have found that an investigational treatment combination of a therapeutic vaccine and an immune-stimulator improves virologic control and delays viral rebound following the discontinuation of antiretroviral therapy (ART) in non-human primates infected with SIV, the simian form of HIV.
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.
The American Society for Radiation Oncology (ASTRO) has issued a new Model Policy for proton beam therapy (PBT) that details which cancer diagnoses meet ASTRO's evidence-based standards and should be covered by private insurers and Medicare.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Luis Angel Diaz Cruz, M D Po Box 51502, Toa Baja, PR 00950-1502 Ph: (787) 710-2532 | Dr Luis Angel Diaz Cruz, M D A La Orden Shopping Center 2nd Fl 600, 2821 Pr-167, Toa Baja, PR 00950-1502 Ph: (787) 710-2532 |
News Archive
Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS® CRT-D. The exclusive expanded indication is effective immediately and makes Boston Scientific CRT-Ds the only devices approved by the FDA for patients in all New York Heart Association (NYHA) classes of heart failure.
Spanish researchers have analysed the effect of endurance running training on the stiffness index, a variable that is directly related to bone quality. The results confirm that the greater the race distance that is trained, the better; this can be used, therefore, to prevent the progressive decline in bone mineral density that occurs with age.
Researchers have found that an investigational treatment combination of a therapeutic vaccine and an immune-stimulator improves virologic control and delays viral rebound following the discontinuation of antiretroviral therapy (ART) in non-human primates infected with SIV, the simian form of HIV.
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.
The American Society for Radiation Oncology (ASTRO) has issued a new Model Policy for proton beam therapy (PBT) that details which cancer diagnoses meet ASTRO's evidence-based standards and should be covered by private insurers and Medicare.
› Verified 8 days ago
Angel F. Delgado Garrastegui, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: A La Orden Shopping Center Ave Comerio Norte, #600 2nd Floor 2821 Pr-167, Toa Baja, PR 00949 Phone: 787-710-2532 | |
Dr. Servanda C Fleitas Macias, Nephrology Medicare: May Accept Medicare Assignments Practice Location: Hf16 Calle Lizzie Graham, 7ma Seccion Levittown, Toa Baja, PR 00949 Phone: 787-795-2935 Fax: 787-784-0680 | |
Veronica Alana Vestal, MD Nephrology Medicare: Medicare Enrolled Practice Location: 7056 Via Playera, Toa Baja, PR 00949 Phone: 787-533-1093 | |
Maria De Lourdes Miranda, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: Aa3 Ave Don Pelayo, Urb.covadonga, Toa Baja, PR 00949 Phone: 787-251-1414 Fax: 787-765-5147 | |
Dr. Natalie Rodriguez Desalden, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Rh8 Calle Acacia, Levittown, Toa Baja, PR 00949 Phone: 939-338-1526 Fax: 939-338-1526 | |
Agustin Gabriel Velazquez Perez, Nephrology Medicare: Accepting Medicare Assignments Practice Location: A La Orden Shopping Center 2nd Fl 600, Toa Baja, PR 00949 Phone: 787-710-2532 |